



Docket: 7213.13


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Charles N. Serhan	
Application No.:	10/663,061	
Filing Date:	September 12, 2003	Examiner:
Title:	Aspirin-Triggered Lipid Mediators	Group Art Unit:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97(B)**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this document is being sent via First Class U.S. mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 18th day of DEC, 2003.


(Signature)

Dear Sir:

Pursuant to 37 CFR § 1.97(b), the references listed on the attached Form PTO-1449 (1 sheet, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the identified references are enclosed as necessary. This IDS is being filed before the mailing of a first office action on the merits. In accordance with 37 CFR § 1.97(b), no statement or fee is required.


Additionally, a Protest Under 37 CFR § 1.291(a) and a Third Party Submission of Patents or Publications Under 37 CFR § 1.99 were filed in the parent application (U.S. Ser. No. 09/785,866). Copies of these documents and the references are being supplied herewith.

It should be noted that U.S. Patent No. 5,409,955, issued to Bockow et al., was cited in the parent application and is also cited in the Information Disclosure Statement under 37 CFR § 1.97(b) attached herewith.

Respectfully submitted,

DORSEY & WHITNEY LLP
Customer Number 25763

Date: December 17, 2003

By: 
Scott D. Rothenberger
Reg. No. 41,277
Intellectual Property Department
Suite 1500
50 South Sixth Street
Minneapolis, MN 55402-1498
(612) 340-8819



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/663,061
Filing Date	September 12, 2003
First Named Inventor	Charles N. Serhan
Art Unit	
Examiner Name	

Sheet	1	of	1	Attorney Docket Number	7213.13
-------	---	----	---	------------------------	---------

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
		Eritsland et al., "Effects of Highly Concentrated Omega-3 PUF As and Acetylsalicylic Acid, Alone and Combined, on Bleeding Time and Serum Liquid Profile", <i>J, Olso City Hosp.</i> , Vol. 39 (8-9), pp. 97-101, 1989.	<input type="checkbox"/>	<input type="checkbox"/>
		Iacoviello et al., "Modulation of Fibrinolytic Response to Venous Occlusion in Humans by a Combination of Low-Dose Aspirin and n-3 PUFAs", <i>Arteriosclerosis Thrombosis</i> , Vol. 10, pp. 1191-1197, 1992.	<input type="checkbox"/>	<input type="checkbox"/>
		Lau et al., "Effects of Fish Oil Supplementation on Non-Steroidal Anti-Inflammatory Drug (NSAID) Requirement in Patients with Mild Rheumatoid Arthritis - A Double-Blind Placebo Controlled Study", <i>British Journal of Rheumatology</i> , Vol. 32 (11), pp. 982-989. 1993.	<input type="checkbox"/>	<input type="checkbox"/>
		Rao et al., "Comparative Pharmacology of Cyclooxygenase Inhibitors on Platelet Function", <i>Prostaglandins Leukot. Med.</i> , Vol. 18 (1), pp. 119-131, 1985	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.